argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022 01:00 ET
|
argenx SE
October 20, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
September 21, 2022 01:00 ET
|
argenx SE
Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod...
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
September 21, 2022 01:00 ET
|
argenx SE
Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study...
argenx Appoints Camilla Sylvest to Board of Directors
September 08, 2022 14:10 ET
|
argenx SE
September 8, 2022 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx to Present at Wells Fargo Healthcare Conference
August 31, 2022 01:00 ET
|
argenx SE
August 31, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
August 11, 2022 07:00 ET
|
argenx SE
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)...
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022 02:30 ET
|
argenx SE
July 28, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022 01:00 ET
|
argenx SE
$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022Biologics License...
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
July 21, 2022 01:00 ET
|
argenx SE
July 21, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
June 24, 2022 01:00 ET
|
argenx SE
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing...